NEW YORK (GenomeWeb News) – Epigenomics today said that it has signed a collaboration and licensing agreement with Royal Philips Electronics to develop a molecular diagnostics platform for running cancer tests.
The firms will jointly perform feasibility studies aimed at developing a fully automated instrument platform for diagnosing certain cancers based on DNA methylation biomarkers.
As part of the pact, Philips obtained the option to license the technologies and biomarkers separately or in combination for diagnostic applications. The Dutch electronics and medical imaging equipment firm may exercise the option upon successful completion of the feasibility studies, said Epigenomics.
Financial details of the agreement were not disclosed.